ASCO Plenary – Gilead and Arcus pedal hard with TIGIT
A domvanalimab triplet shows some promise in high PD-L1-expressing gastric cancer patients, but caveats abound.
CTOS 2023 – IDRx looks to outdo Deciphera
A 14% ORR with IDRX-42 in fourth-line GIST looks better than the 9% previously seen with Qinlock.
Interview – Coherus sees the stars aligning at last
After two years Loqtorzi is on the US market at last, and Coherus looks to its Surface acquisition to play the combo game.
SITC 2023 – Aulos and Xilio press on with cytokine approaches
But the groups have yet to see any responses with AU-007 and XTX202 respectively.
ASH 2023 preview – small-molecule duels
The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.
ASH 2023 preview – the first cell therapy winners
Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.
Schrödinger jumps on the PRMT5 bandwagon
Meanwhile, Bristol Myers Squibb hands back two mystery projects.
